Using CD3-depletion or NK-enriched CD56 positive killer cells will certainly minimize any potential risks of GVHD in patients that may remain immunosuppressed by prior anti-cancer modalities or SCT, since an extended circulation time of IMAK is likely to increase the risk of GVHD. The gene discussed is NCAM1; the disease is cancer.